Top Story

RUBY-I: Preliminary study shows safety of 3D + ribavirin in CKD

April 25, 2015

VIENNA — A small cohort of patients with chronic kidney disease demonstrated favorable tolerability outcomes with the Viekira Pak, according to data presented during the Late Breaker session at the 2015 International Liver Congress.

HCV Next Editorial Board member Paul J. Pockros, MD, of Scripps Clinic in La Jolla, California, presented interim data for patients treated with Viekira Pak (ombitasvir, paritaprevir,  ritonavir plus dasabuvir; Abbvie) daily with or without ribavirin 200 mg every day. Patients with genotype 1b disease were treated without ribavirin, and the genotype 1a patients received ribavirin.

Meeting News Coverage

REP 2139 found to reduce HBsAg in Caucasians with HBV/HDV coinfection

April 25, 2015
VIENNA — In a phase 2 clinical trial, the nucleic acid polymer REP 2139 reduced hepatitis B surface antigen serum in Caucasian patients with hepatitis B and D…
Meeting News Coverage

BOSON: Sovaldi plus PEG-RBV improved SVR12 in genotype 3 HCV

April 25, 2015
VIENNA — Twelve weeks of therapy with Sovaldi plus peginterferon and ribavirin was associated with 12-week sustained virologic response rates higher than 90% in…
Meeting News Coverage

Statin use in HCV patients may lower risk of death, decompensation

April 25, 2015
VIENNA — Statin use in patients with hepatitis C virus and compensated cirrhosis seems to offer a protective effect against death and decompensation, according to…
Meeting News Coverage

Harvoni induces high response rates in genotype 4, 5 HCV

April 25, 2015
VIENNA — Patients with genotype 4 and 5 hepatitis C virus benefitted from treatment with Harvoni, according to findings presented at the 2015 International Liver…
More News Headlines »
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
Meeting News Coverage Video
VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

VIDEO: Effectiveness of inactivated vs. live flu vaccine currently unclear

April 24, 2015
BETHESDA, Md. — Richard K. Zimmerman, MD, of the University of Pittsburgh, explains the results of his study…
More »
CME
Management of Pediatric Conjunctivitis and Otitis/Conjunctivitis Syndrome

Management of Pediatric Conjunctivitis and Otitis/Conjunctivitis Syndrome

This activity is supported by an educational grant from Alcon Research, LTD.

More »
morganatic-roan
morganatic-roan